πŸ”₯πŸ” BizChicken πŸ”πŸ”₯

Companies Similar to Cadrenal Therapeutics, Inc. Common Stock

Sign Up Today!

Sign up for BizChicken and discover more about the corporations around you.

CARGO Therapeutics, Inc. Common Stock

CARGO Therapeutics, Inc. Common Stock logo
Market Cap: Medium
Employees: Low

CRG-022

CARGO Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing chimeric antigen receptor (CAR) T-cell therapies for cancer patients. Their lead program, CRG-022, targets resistance mechanisms in B-cell malignancies.

Tags: B-cell Malignancies, Biotechnology, CAR T-cell Therapies, Cancer Treatment, Clinical-stage

Symbol: CRGX

Recent Price: $13.76

Industry: Biotechnology

CEO: Ms. Gina Chapman

Sector: Healthcare

Employees: 150

Address: 1900 Alameda De Las Pulgas, San Mateo, null 94403

Phone: 650-379-6143

Leadership

  • Gina Chapman, President and Chief Executive Officer
  • Anup Radhakrishnan, Chief Financial Officer/Chief Business Officer
  • Ginna Laport, MD, Chief Medical Officer
  • Shishir Gadam, PhD, Chief Technical Officer
  • Michael Ports, PhD, Chief Scientific Officer
  • Kari Leetch, Chief People Officer
  • Halley Gilbert, JD, Chief Legal Officer
  • Bethany Rogers, SVP, Product Strategy and Commercialization
  • Faisal Shawwa, SVP, Finance
  • Tonia J. Buchholz, PhD, Head of Clinical Science
  • Kanika Chawla, PhD, Head of Process Sciences
  • Sandra Chen, Head of Clinical Quality and Risk Management
  • Michelle Gray, Head of Clinical Operations
  • Adam Haskett, Head of External Manufacturing
  • David Hoffman, JD, Head of Intellectual Property & Transactions
  • Anissa Irwin, Head of Quality Assurance and Systems
  • Brett Masterson, Head of Marketing
  • Rob McCombie, Head of CMC Regulatory
  • Frank McDonald, Head of Clinical Data Management
  • Priya Parameswaran, Head of Corporate Strategy and Business Operations
  • Shabnum Patel, PHD, Head of MSAT
  • Mary Rodley, Head of CMC Strategy and Operations
  • Abhijeet Sarvaiya, Head of Statistical Programming
  • Brian Schoelkopf, Head of FP&A
  • Christophe Suchet, Head of IT
  • Beth Vasievich, PhD, Head of Commercial Planning and Operations
  • Jun Wang, Head of Procurement
  • John Orwin, Chairman of the Board
  • Abraham Bassan, Board Director
  • Kapil Dhingra, M.B.B.S, Board Director
  • Reid Huber, PHD, Board Director
  • David Lubner, Board Director
  • Krishnan Viswanadhan, Pharm.D, Board Director
  • Jane Pritchett Henderson, Board Director

Last updated: 2024-12-31

Candel Therapeutics, Inc.

Candel Therapeutics, Inc. logo
Market Cap: Low
Employees: Lowest

CAN-2409, CAN-3110

Candel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing immunotherapies for cancer patients, with products like CAN-2409 and CAN-3110 in various clinical trial phases.

Tags: biopharmaceutical, cancer treatment, clinical trials, immunotherapies

Symbol: CADL

Recent Price: $7.95

Industry: Biotechnology

CEO: Dr. Paul-Peter Tak FOCIS, M.D., Ph.D.

Sector: Healthcare

Employees: 42

Address: 117 Kendrick Street, Needham, MA 02494

Phone: 617 916 5445

Last updated: 2024-12-31

Contineum Therapeutics, Inc. Class A Common Stock

Contineum Therapeutics, Inc. Class A Common Stock logo
Market Cap: Medium
Employees: Lowest

PIPE-791

Contineum Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need.

Tags: biopharmaceutical, immunology, inflammation, neuroscience, pipeline

Symbol: CTNM

Recent Price: $14.47

Industry: Biotechnology

CEO: Mr. Carmine N. Stengone MBA, MS

Sector: Healthcare

Employees: 31

Address: 10578 Science Center Drive, San Diego, CA 92121

Phone: (858) 333-5280

Leadership

  • Carmine Stengone, President and Chief Executive Officer
  • Austin Chen, PhD, Senior Vice President, Head of Research
  • Beverly Dixon, Senior Director, Quality Assurance
  • Kristina Haeckl, Sr. Vice President, Regulatory Affairs
  • Daniel Lorrain, PhD, Chief Scientific Officer
  • John Healy, General Counsel & Corporate Secretary
  • Jon Seiders, PhD, Vice President, CMC
  • Jules Lee, Senior Director, Clinical Operations
  • Julie Iwashita, Vice President, Clinical Operations
  • Karin Stebbins, Vice President, Toxicology
  • Michael Mayberry, Vice President, Finance
  • Mike Poon, PhD, Vice President, Biology
  • Peter Slover, Chief Financial Officer
  • Stephen Huhn, MD, Chief Medical Officer & Senior Vice President, Clinical Development
  • Tara Vargas, Senior Director, Project Management
  • Thomas O. Schrader, PhD, Senior Director, Chemistry
  • Varsha Dourado, Vice President, Business Development

Last updated: 2024-12-31

Capricor Therapeutics, Inc.

Capricor Therapeutics, Inc. logo
Market Cap: Medium
Employees: Low

CAP-1002

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company specializing in developing transformative cell and exosome-based therapeutics aimed at treating and preventing a range of diseases and disorders. Their lead candidate, CAP-1002, is designed for Duchenne muscular dystrophy and cytokine storm interventions.

Tags: COVID-19, Duchenne muscular dystrophy, biotechnology, cell therapy, therapeutics

Symbol: CAPR

Recent Price: $13.76

Industry: Biotechnology

CEO: Dr. Linda MarbΓ‘n Ph.D.

Sector: Healthcare

Employees: 101

Address: 10865 Road to the Cure, San Diego, CA 92121

Phone: 310 358 3200

Leadership

  • Linda MarbΓ‘n, Ph.D., Chief Executive Officer and Director
  • Kristi A. H. Elliott, Ph.D., Chief Science Officer
  • AJ Bergmann, M.B.A., Chief Financial Officer
  • Karen G. Krasney, J.D., Executive Vice President and General Counsel
  • Mark Awadalla, Vice President of Clinical Operations
  • Jonathan Tayco, Vice President of Program Management and Business Operations
  • Minghao Sun, Ph.D., Vice President of Research and Product Development
  • Yushi Feng, Ph.D., Vice President of Regulatory Affairs
  • Frank Litvack M.D., FACC, Executive Chairman
  • Paul G. Auwaerter, M.D., M.B.A., FIDSA, Director
  • Earl M. (Duke) Collier Jr., Director
  • George W. Dunbar, Jr., Director
  • Philip J. Gotwals, Ph.D., Director
  • Michael Kelliher, Director
  • David B. Musket, Director
  • Karimah Es Sabar, Director

Last updated: 2024-12-31

Neumora Therapeutics, Inc. Common Stock

Neumora Therapeutics, Inc. Common Stock logo
Market Cap: High
Employees: Low

navacaprant (NMRA-140)

Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. Key programs include navacaprant for major depressive disorder, and several promising treatments in various stages of clinical and preclinical trials targeting conditions such as Alzheimer's, schizophrenia, and Parkinson's disease.

Tags: biopharmaceutical, brain diseases, clinical trials, neurodegenerative diseases, neuropsychiatric disorders

Symbol: NMRA

Recent Price: $11.06

Industry: Biotechnology

CEO: Mr. Henry O. Gosebruch

Sector: Healthcare

Employees: 108

Address: 490 Arsenal Way, Watertown, null 02472

Phone: 857 760 0900

Last updated: 2024-12-31

Telomir Pharmaceuticals, Inc. Common Stock

Telomir Pharmaceuticals, Inc. Common Stock logo
Market Cap: Low
Employees: Lowest

TELOMIR-1

Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on developing and commercializing therapies for age-related inflammatory conditions and post-chemotherapy recovery.

Tags: TELOMIR-1, inflammatory conditions, pharmaceutical, stem cells, therapeutic treatment

Symbol: TELO

Recent Price: $4.64

Industry: Biotechnology

CEO: Mr. Erez Aminov

Sector: Healthcare

Employees: 1

Address: 855 N Wolfe Street, Baltimore, null 21205

Phone: (737)-289-0835

Last updated: 2024-12-31

Tenax Therapeutics, Inc.

Tenax Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

TNX-103, TNX-102 (levosimendan), TNX-201 (imatinib)

Tenax Therapeutics, Inc. is a specialty pharmaceutical company that focuses on identifying, developing, and commercializing products for cardiovascular and pulmonary diseases. The company is involved in developing medications such as TNX-103 and TNX-102 (levosimendan) for pulmonary hypertension and heart failure, and TNX-201 (imatinib) for pulmonary arterial hypertension.

Tags: TNX-102, TNX-103, TNX-201, cardiovascular, pharmaceutical, pulmonary diseases

Symbol: TENX

Recent Price: $6.55

Industry: Biotechnology

CEO: Mr. Christopher T. Giordano

Sector: Healthcare

Employees: 5

Address: ONE Copley Parkway, Morrisville, NC 27560

Phone: 919 855 2100

Last updated: 2024-12-31

Tenaya Therapeutics, Inc.

Tenaya Therapeutics, Inc. logo
Market Cap: Low
Employees: Low

TN-201, TN-301, TN-401

Tenaya Therapeutics, Inc. is a biotechnology company that discovers, develops, and delivers therapies for heart disease using cellular regeneration, gene therapy, and precision medicine platforms.

Tags: biotechnology, gene therapy, heart disease, precision medicine, therapeutics

Symbol: TNYA

Recent Price: $1.45

Industry: Biotechnology

CEO: Mr. Faraz Ali M.B.A.

Sector: Healthcare

Employees: 140

Address: 171 Oyster Point Boulevard, South San Francisco, CA 94080

Phone: 650 825 6900

Last updated: 2024-12-31

Travere Therapeutics, Inc.

Travere Therapeutics, Inc. logo
Market Cap: Medium
Employees: Medium

Chenodal, Cholbam, Thiola, Sparsentan, TVT-058

Travere Therapeutics, Inc. is a biopharmaceutical company that focuses on identifying, developing, commercializing, and delivering therapies for the treatment of rare diseases. Its products include Chenodal, Cholbam, Thiola, and candidates like Sparsentan and TVT-058.

Tags: Chenodal, Cholbam, Sparsentan, TVT-058, Thiola, biopharmaceutical, rare diseases, therapeutics

Symbol: TVTX

Recent Price: $17.32

Industry: Biotechnology

CEO: Dr. Eric M. Dube Ph.D.

Sector: Healthcare

Employees: 380

Address: 3611 Valley Centre Drive, San Diego, CA 92130

Phone: 888 969 7879

Leadership

  • Eric Dube, Ph.D., President & Chief Executive Officer
  • Chris Cline, CFA, Chief Financial Officer
  • Angela Giannantonio, Senior Vice President, Human Resources
  • Peter Heerma, Chief Commercial Officer
  • Jula Inrig, M.D., Chief Medical Officer
  • Casey Logan, Chief Business Officer
  • Elizabeth Reed, J.D., Senior Vice President, General Counsel, Corporate Secretary
  • William Rote, Ph.D., Senior Vice President, Research & Development
  • Charlotte Smith, Senior Vice President, Public Affairs
  • Gary A. Lyons, Chairman
  • Roy D. Baynes, M.D., Ph.D.,
  • Suzanne L. Bruhn, Ph.D.,
  • Tim Coughlin, CPA,
  • Jeffrey A. Meckler,
  • John A. Orwin,
  • Sandra E. Poole,
  • Ron Squarer,
  • Ruth Williams-Brinkley, FACHE,

Last updated: 2024-12-31

Biomerica, Inc.

Biomerica, Inc. logo
Market Cap: Lowest
Employees: Low

diagnostic and therapeutic products

Biomerica, Inc. is a biomedical technology company that develops, patents, manufactures, and markets diagnostic and therapeutic products for medical conditions and diseases worldwide, focusing on gastrointestinal diseases, food intolerances, and diabetes.

Tags: biomedical, diabetes, diagnostic, food intolerances, gastrointestinal, therapeutic

Symbol: BMRA

Recent Price: $0.31

Industry: Medical - Devices

CEO: Mr. Zackary S. Irani

Sector: Healthcare

Employees: 64

Address: 17571 Von Karman Avenue, Irvine, CA 92614

Phone: 949 645 2111

Last updated: 2024-12-31

Cumberland Pharmaceuticals Inc.

Cumberland Pharmaceuticals Inc. logo
Market Cap: Lowest
Employees: Low

Acetadote, Caldolor, Kristalose, Omeclamox-Pak, Vaprisol, Vibativ, Redi Trex

Cumberland Pharmaceuticals Inc. focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, rheumatology, and oncology, offering various medications including injections and oral solutions.

Tags: gastroenterology, hospital care, oncology, pharmaceutical, prescription products, rheumatology

Symbol: CPIX

Recent Price: $2.42

Industry: Drug Manufacturers - Specialty & Generic

CEO: Mr. A. J. Kazimi MBA

Sector: Healthcare

Employees: 91

Address: 2525 West End Avenue, Nashville, TN 37203

Phone: 615 255 0068

Last updated: 2024-12-31

Mineralys Therapeutics, Inc.

Mineralys Therapeutics, Inc. logo
Market Cap: Medium
Employees: Lowest

lorundrostat

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for hypertension and associated cardiovascular diseases, with its lead product candidate being lorundrostat.

Tags: biopharmaceutical, cardiovascular diseases, hypertension, lorundrostat, therapies

Symbol: MLYS

Recent Price: $12.52

Industry: Biotechnology

CEO: Mr. Jon Congleton

Sector: Healthcare

Employees: 28

Address: 150 N. Radnor Chester Rd., Radnor, PA 19087

Phone: 888-378-6240

Last updated: 2024-12-31

PTC Therapeutics, Inc.

PTC Therapeutics, Inc. logo
Market Cap: High
Employees: Medium

Translarna, Emflaza, Tegsedi, Waylivra, Evrysdi

PTC Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering, developing, and commercializing medicines for patients with rare disorders. The company offers a portfolio of products including treatments for Duchenne muscular dystrophy, rare diseases, and spinal muscular atrophy.

Tags: Duchenne muscular dystrophy, biopharmaceutical, medicine development, rare disorders, spinal muscular atrophy

Symbol: PTCT

Recent Price: $45.77

Industry: Biotechnology

CEO: Dr. Matthew B. Klein F.A.C.S., M.D., M.S.

Sector: Healthcare

Employees: 988

Address: 100 Corporate Court, South Plainfield, NJ 07080

Phone: 908 222 7000

Leadership

  • Matthew B. Klein, M.D., M.S., F.A.C.S., CEO, PTC Therapeutics, Inc.
  • Neil Almstead, Ph.D., Chief Technical Operations Officer
  • John Baird, Ph.D., Chief of Staff to the CEO
  • Mark E. Boulding, Executive Vice President and Chief Legal Officer
  • Lee Golden, M.D., Chief Medical Officer
  • Pierre Gravier, Chief Financial Officer
  • Mary Frances Harmon, Senior Vice President, Corporate and Patient Relations
  • Linda Montella-Carter, Senior Vice President and Chief Information Officer
  • Eric Pauwels, Chief Business Officer
  • Hege Sollie-Zetlmayer, Chief Human Resources Officer
  • Christine Utter, Senior Vice President, Chief Accounting Officer and Head of People Services
  • Michael Schmertzler, Chairman
  • William F. Bell, Jr., Managing Director and Head of Healthcare Services Practice, L.E.K. Consulting
  • Allan Jacobson, Ph.D., University of Massachusetts Chan Medical School
  • Stephanie S. Okey, M.S., Former SVP, Head of North America, Rare Disease – Genzyme
  • Emma Reeve, Independent Board Director
  • Mary Smith, The VENG Group
  • David P. Southwell, Former CEO, TScan Therapeutics
  • Glenn D. Steele, Jr., M.D., Ph.D., Chairman, GSteele Health Solutions
  • Alethia Young, Chief Financial Officer, Bicycle Therapeutics
  • Jerome B. Zeldis, M.D., Ph.D., Independent Board Director

Last updated: 2024-12-31

TransCode Therapeutics, Inc.

TransCode Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

TTX-MC138

Trans Code Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing drugs and diagnostics for treating metastatic disease. Their lead product, TTX-MC138, is aimed at metastatic cancer treatment, along with a range of other therapeutic platforms targeting cancer through innovative RNA- and CRISPR-based technologies.

Tags: CRISPR technology, RNA-based therapy, biopharmaceutical, cancer treatment, metastatic disease

Symbol: RNAZ

Recent Price: $3.76

Industry: Biotechnology

CEO: Mr. Thomas A. Fitzgerald M.B.A.

Sector: Healthcare

Employees: 10

Address: 6 Liberty Square, Boston, MA 02109

Phone: 857-837-3099

Last updated: 2024-12-31

Syros Pharmaceuticals, Inc.

Syros Pharmaceuticals, Inc. logo
Market Cap: Lowest
Employees: Low

Tamibarotene

Syros Pharmaceuticals is a biopharmaceutical company focused on developing treatments for cancer and monogenic diseases through gene control medicines. Key products include Tamibarotene for myelodysplastic syndrome and acute myeloid leukemia, and SY-5609 for advanced solid tumors.

Tags: acute myeloid leukemia, biopharmaceutical, cancer treatment, gene control, myelodysplastic syndrome, pharmaceutical development

Symbol: SYRS

Recent Price: $0.25

Industry: Biotechnology

CEO: Mr. Conley Chee

Sector: Healthcare

Employees: 68

Address: 35 CambridgePark Drive, Cambridge, MA 02140

Phone: 617 744 1340

Leadership

  • Conley Chee, President and Chief Executive Officer
  • Jason Haas, Chief Financial Officer
  • Gerald E. Quirk, Chief Legal & Compliance Officer; Chief Business Officer
  • Lisa Roberts, VP Human Resources
  • David A. Roth, M.D., Chief Medical Officer
  • Kristin Stephens, Chief Development Officer

Last updated: 2024-12-31

TRACON Pharmaceuticals, Inc.

TRACON Pharmaceuticals, Inc. logo
Market Cap: Lowest
Employees: Lowest

therapeutics for cancer

TRACON Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing cancer therapeutics, including clinical stage products like envafolimab, YH001, TRC102, and TJ004309, with collaboration agreements with various biopharmaceutical companies.

Tags: TJ004309, TRC102, YH001, biopharmaceutical, cancer therapeutics, clinical trials, envafolimab

Symbol: TCON

Recent Price: $0.03

Industry: Biotechnology

CEO: Mr. Craig R. Jalbert CIRA

Sector: Healthcare

Employees: 17

Address: 4350 La Jolla Village Drive, San Diego, CA 92122

Phone: 858 550 0780

Last updated: 2024-12-31

Verve Therapeutics, Inc.

Verve Therapeutics, Inc. logo
Market Cap: Medium
Employees: Low

VERVE-101

Verve Therapeutics, Inc. is a genetic medicines company developing gene editing treatments for cardiovascular diseases, primarily through its lead product VERVE-101.

Tags: VERVE-101, biotechnology, cardiovascular diseases, gene editing, genetic medicines

Symbol: VERV

Recent Price: $5.54

Industry: Biotechnology

CEO: Dr. Sekar Kathiresan M.D.

Sector: Healthcare

Employees: 255

Address: 500 Technology Square, Cambridge, MA 02139

Phone: 617 603 0070

Leadership

  • Andrew Ashe, President, Chief Operating Officer and General Counsel
  • Victoria Bartlett, Vice President, Program and Alliance Management
  • Dan Balian, Associate Director, Supply Chain Management
  • Allen Barrett, Director, Corporate Counsel

Last updated: 2024-12-31

Catalent, Inc.

Catalent, Inc. logo
Market Cap: Highest
Employees: Highest

Drug and health product solutions

Catalent, Inc. develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products globally. It operates through segments like Biologics, Softgel and Oral Technologies, among others.

Tags: Biologics, Biotech, Drug Development, Gene Therapy, Health Products, Pharmaceuticals

Symbol: CTLT

Recent Price: $63.48

Industry: Drug Manufacturers - Specialty & Generic

CEO: Mr. Alessandro Maselli

Sector: Healthcare

Employees: 17000

Address: 14 Schoolhouse Road, Somerset, NJ 08873

Phone: 732 537 6200

Last updated: 2024-12-31

Cadrenal Therapeutics, Inc. Common Stock

Cadrenal Therapeutics, Inc. Common Stock logo
Market Cap: Lowest
Employees: Lowest

Tecarfarin

Cadrenal Therapeutics, Inc. is a clinical development biopharmaceutical company focusing on novel therapies for preventing systemic thromboembolism in patients with specific health conditions, headquartered in Ponte Vedra, Florida.

Tags: Tecarfarin, atrial fibrillation, biopharmaceutical, cardiac, clinical development, end-stage renal disease, orphan drug, systemic thromboembolism

Symbol: CVKD

Recent Price: $14.23

Industry: Biotechnology

CEO: Mr. Quang X. Pham

Sector: Healthcare

Employees: 4

Address: 822 A1A North, Ponte Vedra, FL 32082

Phone: 904 300 0701

Last updated: 2024-12-31

Larimar Therapeutics, Inc.

Larimar Therapeutics, Inc. logo
Market Cap: Medium
Employees: Lowest

CTI-1601

Larimar Therapeutics, Inc. is a clinical-stage biotechnology company developing treatments for rare diseases using a novel cell penetrating peptide technology platform. Their lead product candidate, CTI-1601, is undergoing Phase 1 clinical trials to treat Friedreich's ataxia.

Tags: Friedreich's ataxia, biotechnology, cell penetrating peptide, clinical-stage, novel technologies, rare diseases

Symbol: LRMR

Recent Price: $3.91

Industry: Biotechnology

CEO: Dr. Carole S. Ben-Maimon M.D.

Sector: Healthcare

Employees: 42

Address: Three Bala Plaza East, Bala Cynwyd, PA 19004

Phone: 844 511 9056

Leadership

  • Carole Ben-Maimon, MD, President and Chief Executive Officer
  • Gopi Shankar, PhD, MBA, FAAPS, Chief Development Officer
  • Rusty Clayton, DO, Chief Medical Officer
  • Michael Celano, CHIEF FINANCIAL OFFICER
  • John Berman, Vice President of Finance and Administration
  • Jennifer Johansson, Vice President, Legal and Compliance
  • Keith E. Lynch, Jr., Vice President, CMC Technical Operations
  • Noreen Scherer, Vice President of Clinical Operations
  • Francis Michael Conway, CPA, VICE PRESIDENT AND CONTROLLER
  • Mohamed Hamdani, Vice President, Statistics and Quantitative Sciences
  • Adrienne Clements-Egan, Ph.D., Vice President, Bioanalytics and Developability
  • Frank Nazzario, RPh, Vice President, Commercial
  • Joseph Truitt, BOARD CHAIR
  • Tom Hamilton,
  • Jonathan Leff,
  • Frank E. Thomas,
  • Jeffrey Sherman, MD,
  • ,

Last updated: 2024-12-31